STOCKS TELEGRAPH

Tag: BFRA

  • Biofrontera AG (BFRA) stock has skyrocketed to 13.09% – What’s helping it to move high?

    Biofrontera AG (BFRA) stock has skyrocketed to 13.09% – What’s helping it to move high?

    Biofrontera AG (BFRA) experienced an increase of 13.09% in premarket. The rally seems to follow discussions on social media sites like Reddit. However, the last trading session concluded at $2.98 with an increase of 7.19%.

    Mediation Results by BFRA – What’s up?

    On 19th November 2021, BFRA announced that for the past year, Biofrontera AG has already been in dialogue with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG to resolve legal challenges and other disagreements. Moreover, Mr. Zours is an indirect primary shareholder in Biofrontera AG, owning shares in the company through a variety of businesses. Maruho Deutschland GmbH, a subsidiary of Maruho Co. Ltd. in Japan, is another important shareholder. During the dispute settlement system, the Deutsche Balaton Group and the incumbent Supervisory Board of Biofrontera AG agreed on the Supervisory Board nominees.

    Third Quarter 2021 Results – How was the quarter?

    BFRA reported third-quarter 2021 results on 17th November 2021. The company announced that product revenues came out to be EUR 12,334 thousand. Not only this but cash and cash equivalents were EUR 29,539 thousand. Sales in other European nations climbed by 64% over the reporting year, from EUR 1,349 thousand in 2020 to EUR 2,208 thousand. Biofrontera was able to secure a new license agreement in Europe. European sales include a one-time payment of EUR 50,000 made to the company upon contract completion.

    Moreover, BFRA reflects back on a good nine-month period in 2021, with to considerable business continuity plan in the second and third quarters. Product sales have been returned to pre-pandemic values since the beginning of 2021. Despite the fact that the pandemic had a significant impact on the first few months, the situation has improved significantly.

    Initiation of Clinical Studies – Worth it?

    On 16th November 2021, BFRA reported that clinical studies have been initiated. The studies will improve marketing strategy and increase market share in the main market, the United States, for the FDA-approved prescription drug Ameluz for photodynamic therapy. Last but not the least, patient recruitment will begin before the end of the year.

    About BFRA

    Biofrontera AG is a pharmaceutical firm focused on the research and marketing of dermatological medication and cosmetics. The company, which is based in Germany, creates and sells cutting-edge skin-care, protection, and therapy products. The combination of Ameluz, a topical prescription medication, and the medical equipment BF-RhodoLED for photodynamic therapy of such superficial skin malignancies and precursors is the firm’s main product. Since 2012, Ameluz has been available in the European Union, and since May 2016, it has been available in the United States. In the European Union, the business also sells Belixos, a dermo-cosmetics line that provides specialized skincare for damaged or diseased skin.

  • Now Is Good Time To Buy Biofrontera (NASDAQ: BFRA) Stock?

    Now Is Good Time To Buy Biofrontera (NASDAQ: BFRA) Stock?

    Biofrontera AG (NASDAQ: BFRA) has announced a mutual agreement with Mr. Wilhelm K.T. Zours and Deutsche Balaton AG to discuss the key elements of the mediation agreement. Biofrontera AG planned to resolve legal disputes through the mediation agreement. Mr. Zours is chairman of the supervisory board and majority shareholder of Deutsche Balaton AG. He is the major shareholder of the company.

    There are various legal disputes unresolved between the Company on one side and Deutsche Balaton AG together with other companies in which Mr. Zours holds a majority interest on the other side. One of the legal dispute is also pending in the USA.

    As per the mediation process, an experienced and renowned mediator will be involved in the process to find the solutions for the settlement of disputes. There were various disagreements on personnel and strategic corporate matters. The mediation process is expected to start shortly.

    Shares of Biofrontera AG has traded up 18.97% as it gained +1.40 during the trading of Friday. It has a closing price of $8.78. In the past 52-weeks of trading, Biofrontera AG stock fluctuated between the low of $5.26 and a high of $54.94. It has moved up 66.78% from its 52-weeks low and moved down -84.02% from its 52-weeks high. It had a trading volume of 31.92 million as compared to the average volume of 879.03K. Biofrontera market capitalization has remained high, hitting $196.89 million at the time of writing.

    Biofrontera (BFRA) is scheduled to participate in two upcoming conferences. One is the 2020 Lake Street Capital Markets Best Ideas Growth (BIG4) Conference which is anticipated to take place on September 17, 2020. This is the 4th Best Ideas Growth investor conference which will show the dynamic growth companies. Almost 50 companies executives will meet with institutional investors at this conference.

    The second one is the Baader Investment Conference 2020 which is expected to take place on September 25, 2020. Around 230 companies will participate in this conference. The conference will be held as a hybrid event with on-site as well as virtual presentations amid the global pandemic.

  • 3 Stocks Likely to Start Mid-Week Trading on a High Note

    3 Stocks Likely to Start Mid-Week Trading on a High Note

    The markets are up this afternoon, with the exception of the NASDAQ, which continues to be bogged down by underperforming tech stocks. The improved sentiment comes from increased hopes of a COVID-19 vaccine. This follows news that Russia had given regulatory approval for a vaccine.  In the U.S biopharma companies are also moving fast towards mass production of a vaccine.

    Given that the coronavirus has significantly slowed down the world economy, the markets are optimistic that a breakthrough in the fight against it would restart the global economic engine. News of a vaccine has already seen airlines, cruise ships, and hotel stocks start to gain in value. As markets gain, stocks that have big news such as strong earnings are on the rise. Some of the top performers this afternoon are as below:

    Biofrontera AG [NASDAQ: BFRA]

    Biofrontera AG is a top performer this afternoon and is up by over `100%. This follows the company’s announcement of its subscription price for 1% qualified subordinated convertible bond. In a federal gazette notice dated 29th July 2020, the company stated that it exercising its subscription rights of the bonds from 30th July to 13th August 2020. The company also announced that the subscription price of the bond would be at 100% of the bond’s nominal value, and would be subscribed at 3 Euros.

    Eyenovia Inc [NASDAQ: EYEN]

    Eyenovia Inc is a big gainer this afternoon and is up by 33.62%. This follows the company’s announcement that it had entered into an exclusive licensing agreement for the development and commercialization of MicroPine in China and surrounding regions, including in South Korea. As part of the deal, Eyenovia Inc will get upfront payments totaling to $45.75 million.

    The company will also receive an additional payment that will be premised on the achievement of regulatory milestones such as the start of clinical research in South Korea and Greater China. On top of that, Artic Vision will buy its supply of MicroPine only from Eyenovia.  The company will also pay Eyenovia a single-digit percentage in royalty payments and net sales. Commenting on the deal, Eyenovia CEO Dr. Sean Lanchulev stated that the agreement was a major step in growing the company’s commercial reach.

    Sypris Solutions Inc [NASDAQ: SYPR]

    Sypris Solutions Inc is another top performer this afternoon and is up by 39%.  This follows news that the company had won an initial contract to manufacture and test shipboard systems for Leonardo DRS Naval Electronics. The company stated that production will start this year, but did not diverge more on details of the agreement.